Trials / Conditions / Graft-versus-host Disease (GVHD)

Graft-versus-host Disease (GVHD)

22 registered clinical trials studyying Graft-versus-host Disease (GVHD) — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Vitamin C With Steroids for Gastrointestinal GVHD NCT07197749	Baylor College of Medicine	EARLY_Phase 1
Not Yet Recruiting	Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease NCT06905834	Instituto de Investigación Biomédica de Salamanca	Phase 2
Recruiting	Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention NCT06926595	Milton S. Hershey Medical Center	Phase 2
Withdrawn	5-Azacytidine With Steroids for Gastrointestinal GVHD (5-AZA FOR GVHD) NCT06598332	Baylor College of Medicine	EARLY_Phase 1
Recruiting	Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation NCT06799195	University of Nebraska	Phase 2
Enrolling By Invitation	Effects of Omega-3 Fatty Acids on Acute Graft-versus-Host Disease After Allogeneic Stem Cell Transplantation. NCT07162688	Fujian Medical University	Phase 1 / Phase 2
Recruiting	Dapagliflozin in Allo-HCT for aGVHD NCT06626737	The First Affiliated Hospital of Soochow University	Phase 2
Recruiting	A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolat NCT06615050	Incyte Corporation	Phase 3
Enrolling By Invitation	The Application of Novel Identified CD8 Regulatory Precursors in Inducing Immune Tolerance After Allo-HSCT NCT06864598	Peking University People's Hospital	—
Completed	Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) NCT04167514	CSL Behring	Phase 3
Completed	Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids NCT03616184	University of Nebraska	Phase 2
Completed	GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graf NCT03139604	Incyte Corporation	Phase 3
Completed	A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. H NCT03112603	Incyte Corporation	Phase 3
Completed	A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft NCT02953678	Incyte Corporation	Phase 2
Completed	Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD NCT02614612	Incyte Corporation	Phase 1
Completed	Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoi NCT02342145	Zhongming Zhang	Phase 4
Terminated	Maraviroc as GVHD Prophylaxis in Transplant Recipients NCT02167451	Children's Hospital Medical Center, Cincinnati	Phase 1 / Phase 2
No Longer Available	CliniMACS® CD34+ Reagent System for Expanded Access Use NCT02026934	Joseph Antin	—
Completed	University of Wisconsin hMSC Cell Bank: Bone Marrow Donor Protocol NCT01463475	University of Wisconsin, Madison	N/A
Terminated	Biomarkers in Predicting Response in Patients With Graft-Versus-Host Disease Undergoing Extracorporeal Photoph NCT01324908	Vanderbilt-Ingram Cancer Center	N/A
Approved For Marketing	Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD NCT05722912	Incyte Corporation	—
Approved For Marketing	An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic NCT03147742	Incyte Corporation	—